Unknown

Dataset Information

Depletion of central memory CD8+ T cells might impede the antitumor therapeutic effect of Mogamulizumab.


ABSTRACT: Regulatory T (Treg) cells are important negative regulators of immune homeostasis, but in cancers they tone down the anti-tumor immune response. They are distinguished by high expression levels of the chemokine receptor CCR4, hence their targeting by the anti-CCR4 monoclonal antibody mogamulizumab holds therapeutic promise. Here we show that despite a significant reduction in peripheral effector Treg cells, clinical responses are minimal in a cohort of patients with advanced CCR4-negative solid cancer in a phase Ib study (NCT01929486). Comprehensive immune-monitoring reveals that the abundance of CCR4-expressing central memory CD8+ T cells that are known to play roles in the antitumor immune response is reduced. In long survivors, characterised by lower CCR4 expression in their

SUBMITTER: Maeda Y 

PROVIDER: S-EPMC8671535 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature